John V. Heymach

<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma

Ferdinandos Skoulidis, Michael E. Goldberg, Danielle Greenawalt et al. · Cancer Discovery · 2018 · 1.6K citations · Full text

Medicine, Oncology, Pharmacology +16

Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study

Daniel R. Gomez, Chad Tang, Jianjun Zhang et al. · Journal of Clinical Oncology · 2019 · 1.3K citations · Full text

Medicine, Oncology, Surgery +15

An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Lauren A. Byers, Lixia Diao, Jing Wang et al. · Clinical Cancer Research · 2012 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +17

Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study

Daniel R. Gomez, George R. Blumenschein, Mike Hernández et al. · The Lancet Oncology · 2016 · 1.1K citations · Full text

Medicine, Oncology, Medical Oncology +7

Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing

Jianjun Zhang, Junya Fujimoto, Jianhua Zhang et al. · Science · 2014 · 1K citations

Medicine, Molecular Genetics, Oncology +17